[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574497":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":35,"collaborators":38,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":10,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":10,"studyType":87,"phases":10,"briefSummary":88,"conditions":89,"keywords":10,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Shanghai Zhongshan Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Enrolled patients",null,"The final personalized management strategy is determined based on both current conventional treatment options and physicians' and patients' preferences. The following agents might be applied: proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), alkylating agents, anti-CD38 monoclonal antibodies, bispecific antibodies, and cell therapy, with or without steroids.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Peng Liu, Ph.D","CONTACT","+862164041990 ext 2315","liu.peng@zs-hospital.sh.cn",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Zhongshan Hospital, Fudan University","RECRUITING","Shanghai","Shanghai Municipality","200032","China","CN",{"type":28,"coordinates":29},"Point",[30,31],121.45806,31.22222,{"lat":31,"lon":30},[34],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"type":36,"investigatorFullName":37,"investigatorTitle":20,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Peng Liu",[39,41,43,45,47,49,51,53,56,58,60,62,64,66,68,70,72],{"name":40,"class":6},"Tongji Hospital",{"name":42,"class":6},"Peking University First Hospital",{"name":44,"class":6},"The First Affiliated Hospital with Nanjing Medical University",{"name":46,"class":6},"Zhongshan Hospital Xiamen University",{"name":48,"class":6},"First Affiliated Hospital of Wenzhou Medical University",{"name":50,"class":6},"Sir Run Run Shaw Hospital",{"name":52,"class":6},"Zhangzhou Affiliated Hospital of Fujian Medical University",{"name":54,"class":55},"Huzhou Central Hospital, Affiliated Central Hospital HuZhou University","UNKNOWN",{"name":57,"class":6},"Huadong Hospital",{"name":59,"class":6},"Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University",{"name":61,"class":6},"The Third Affiliated Hospital of Nanjing Medical University",{"name":63,"class":6},"Peking University Shenzhen Hospital",{"name":65,"class":6},"Zhejiang Provincial Tongde Hospital",{"name":67,"class":55},"Shenzhen People's Hospital (the Second Clinical Medical College, Jinan University",{"name":69,"class":55},"Shanghai Geriatric Medical Center (Zhongshan Hospital Fudan University Minhang Campus)",{"name":71,"class":55},"The First Affiliated Hospital, Fujian Medical University",{"name":73,"class":6},"Guangdong Provincial People's Hospital","100574497","longitudinal-data-registry-of-plasma-cell-dyscrasia-100574497",false,"NCT06760052","Longitudinal Data Registry of Plasma Cell Dyscrasia","Longitudinal Data Registry of A Spectrum of Plasma Cell Dyscrasia With Long-term Follow-up","Inclusion Criteria:\n\n* Patients with pathological diagnosis of PCD \\[e.g., symptomatic\u002Fasymptomatic multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), POEMS syndrome, light chain (AL) amyloidosis\\] from 2007 to 2027 in Zhongshan Hospital or other collaborating centers.\n* Patients who had complete diagnostic, treatment, and follow-up records.\n* Patients with full comprehension and signature of the informed consent form (ICF) for participation.\n\nExclusion Criteria:\n\n* Patients who refused to use reliable methods of contraception during pregnancy, lactation, or the age-appropriate period.\n* Patients who suffered from severe mental illness.\n* Patients who were deemed unsuitable for inclusion by the investigator.","ALL","19 Years","99 Years",{"count":85,"type":86},2000,"ESTIMATED","OBSERVATIONAL","The goal of this multicenter observational study is to better understand the clinical and molecular characteristics, disease progression, treatment response, and clinical outcomes of patients with plasma cell dyscrasias, including monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, and light-chain amyloidosis. The study is led by Zhongshan Hospital, Fudan University, in collaboration with 18 other research centers in China. The main questions it aims to answer are:\n\nWhich clinical, laboratory, pathological, immunologic, cytogenetic, and genomic characteristics are associated with disease progression, treatment response, and patient outcomes? How do plasma cell dyscrasias and their underlying clones evolve over time? Can clinical and molecular information be used to develop models that predict disease progression and patient outcomes?\n\nResearchers will collect and analyze historical and prospective clinical data from participating centers and follow patients over time. Participants' clinical course, laboratory and other test results, treatments, disease progression, and outcomes will be recorded and analyzed. This is an observational study and does not assign participants to any specific treatment.",[90],"Multiple Myeloma and Other Plasma Cell Neoplasms","2026-07-30",{"date":93,"type":94},"2026-08-03","ACTUAL",{"date":96,"type":94},"2023-03-01",{"date":98,"type":86},"2028-12-31",{"name":5,"class":6},1]